Skip to content
Clinical Trials – home
ItalyBack to Italy

Clinical trials in Saronno – page 44

2 862 clinical trials in Saronno, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Saronno at a glance
2 862
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

2 862 trials in Saronno

Open in trial search

Study of cemiplimab treatment after surgery in patients with stage II-IIIA non-small cell lung cancer who have not received chemotherapy and have PD-L1 expression of 1% or higher

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:ETOP IBCSG Partners Foundation

Study comparing daratumumab, lenalidomide and dexamethasone followed by linvoseltamab versus continued initial treatment in newly diagnosed multiple myeloma patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Study of BMS-986504 for patients with advanced or metastatic non-small cell lung cancer with homozygous MTAP deletion who have previously received treatment

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Navlimetostat
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study of elacestrant and exemestane treatment for patients with previously treated hormone receptor-positive, HER2-negative metastatic breast cancer with FES-avid lesions

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Elacestrant
  • Sponsor:Istituto Europeo Di Oncologia S.r.l.

Study of RSV vaccine immune response persistence and revaccination safety in adult lung and kidney transplant recipients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:GlaxoSmithKline Biologicals

Study of ficerafusp alfa and pembrolizumab as first treatment for patients with PD-L1-positive recurrent or metastatic head and neck cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ficerafusp alfa
  • Sponsor:Bicara Therapeutics Inc.

Study of ONO-4578 and nivolumab with drug combination for first-line treatment in patients with PD-L1 positive advanced colorectal cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Ono Pharmaceutical Co. Ltd.

Study of SAR444336 in Adults with Microscopic Colitis Who Achieved Clinical Remission with Budesonide Treatment

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:SAR444336
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Treatment with trastuzumab deruxtecan, capecitabine and bevacizumab for patients with HER2-positive metastatic colorectal cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Fondazione GONO G.I.

Safety and Tolerability Study of NBI-1065845 as Additional Treatment for Adults with Major Depressive Disorder

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Osavampator
  • Sponsor:Neurocrine Biosciences Inc.

IgA nephropathy

Recruiting

Study of felzartamab compared to placebo in adults with IgA nephropathy

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Codeine Phosphate
  • Sponsor:Biogen Idec Research Limited

Study of lurbinectedin and irinotecan in adults and young adults with advanced desmoplastic small round cell tumor

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lurbinectedin
  • Sponsor:Italian Sarcoma Group

Other cities in Italy

The busiest research cities in the country

All 230 cities in Italy

Clinical research in Saronno

What the registry says about research in the country

01 Respiratory Oncology

Multiple clinical trials focusing on non-small cell lung cancer (NSCLC) treatments, including studies evaluating novel therapeutic approaches for patients with specific genetic mutations.

  • MET deregulation therapy assessment
  • Second-line combination treatments
  • EGFR mutation targeting

Research emphasizes personalized treatment strategies for advanced and metastatic disease states.

02 Women's Oncology

Comprehensive studies addressing breast cancer and gynecological malignancies, with focus on treatment timing and maintenance therapies.

  • Endocrine-responsive breast cancer treatment
  • Ovarian cancer maintenance therapy
  • BRCA wild-type cancer management

Investigations aim to optimize treatment sequences and improve patient outcomes.

03 Specialized Oncology & Cardiology

Innovative research in renal cell carcinoma treatment and cardiac conditions, particularly focusing on novel therapeutic approaches.

  • Metastatic renal cancer therapy
  • Atrial fibrillation management
  • Targeted combination therapies

Studies evaluate both oncological interventions and cardiovascular treatments for high-risk patients.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.